{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:10:08Z","timestamp":1772820608640,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.humpath.2013.06.003","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T22:16:25Z","timestamp":1378419385000},"page":"2449-2460","source":"Crossref","is-referenced-by-count":11,"title":["Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion"],"prefix":"10.1016","volume":"44","author":[{"given":"Ben","family":"Davidson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoav","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahn M.","family":"Nesland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"K\u00e6rn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuven","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes G.","family":"Trop\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2013.06.003_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.humpath.2013.06.003_bb0010","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ejca.2012.01.031","article-title":"Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in stage IV ovarian cancer?","volume":"48","author":"Trop\u00e9","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2013.06.003_bb0015","series-title":"Serous effusions","year":"2011"},{"key":"10.1016\/j.humpath.2013.06.003_bb0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2013.06.003_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2005.09.022","article-title":"AP-2\u03b3 is a marker of tumor progression in ovarian carcinoma","volume":"100","author":"\u00d8degaard","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1309\/PTBB5BPCKX8K9V69","article-title":"Kallikrein 4 expression is upregulated in ovarian carcinoma cells in effusions","volume":"123","author":"Davidson","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0040","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/cncr.20219","article-title":"Granulin-epithelin precursor (GEP) is a novel prognostic marker in epithelial ovarian cancer","volume":"100","author":"Davidson","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2013.06.003_bb0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2004.09.049","article-title":"HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma","volume":"96","author":"Davidson","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/0008-5472.331.65.1","article-title":"Apolipoprotein E is required for cell proliferation and survival in ovarian cancer","volume":"65","author":"Chen","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2013.06.003_bb0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2006.08.045","article-title":"Heparanase expression correlates with poor survival in metastatic ovarian carcinoma","volume":"104","author":"Davidson","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.humpath.2007.05.014","article-title":"Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma","volume":"39","author":"Davidson","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.humpath.2008.09.019","article-title":"Expression of the peroxisome proliferator-activated receptors (PPAR)-\u03b1, -\u03b2 and -\u03b3 in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival","volume":"40","author":"Davidson","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0070","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ygyno.2006.05.042","article-title":"Expression of the chromatin remodeling factor Rsf-1 in effusions is a novel predictor of poor survival in ovarian carcinoma","volume":"103","author":"Davidson","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0075","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.humpath.2006.12.009","article-title":"Expression and clinical role of the BTB\/POZ protein NAC-1 in ovarian carcinoma effusions","volume":"38","author":"Davidson","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.22426","article-title":"Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma","volume":"109","author":"Kleinberg","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2013.06.003_bb0085","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.humpath.2007.10.002","article-title":"Claudin upregulation in ovarian carcinoma effusions is associated with poor survival","volume":"39","author":"Kleinberg","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0090","doi-asserted-by":"crossref","first-page":"285191","DOI":"10.1155\/2010\/285191","article-title":"Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas","volume":"2010","author":"Ueda","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0095","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/dc.20771","article-title":"MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells","volume":"35","author":"Davidson","year":"2007","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0100","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2008.03.009","article-title":"Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma","volume":"39","author":"Davidson","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.humpath.2008.10.003","article-title":"The diagnostic and prognostic role of the insulin growth factor pathway members IGF-II and IGFBP3 in serous effusions","volume":"40","author":"Slipicevic","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000199447","article-title":"Different expression and clinical role of S100A4 in ovarian carcinoma at different anatomic sites","volume":"30","author":"M\u00e6landsmo","year":"2009","journal-title":"Tumor Biol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/PGP.0b013e31818b0f5e","article-title":"Expression and clinical role of anti-apoptotic proteins of the bag, heat shock and Bcl-2 families in effusions, primary tumors and solid metastases in ovarian carcinoma","volume":"28","author":"Bunkholt Elstrand","year":"2009","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.humpath.2008.10.019","article-title":"Cleaved caspases and NF-\u03baB p65 are prognostic factors in metastatic ovarian carcinoma","volume":"40","author":"Kleinberg","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0125","doi-asserted-by":"crossref","first-page":"e11198","DOI":"10.1371\/journal.pone.0011198","article-title":"Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma","volume":"5","author":"Jinawath","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2013.06.003_bb0130","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.humpath.2009.09.017","article-title":"Mammalian target of rapamycin is a biomarker of poor survival in metastatic ovarian carcinoma","volume":"41","author":"Bunkholt Elstrand","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0135","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.humpath.2010.10.013","article-title":"Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome","volume":"42","author":"Davidson","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0140","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.humpath.2010.10.025","article-title":"Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance","volume":"42","author":"Hetland","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s13277-011-0157-6","article-title":"Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status","volume":"32","author":"Bock","year":"2011","journal-title":"Tumor Biol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-011-1191-x","article-title":"Rab25 is overexpressed in M\u00fcllerian serous carcinoma compared to malignant mesothelioma","volume":"460","author":"Brusegard","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2013.06.003_bb0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.humpath.2011.05.022","article-title":"Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions","volume":"43","author":"Elstrand","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00428-012-1228-9","article-title":"HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors and solid metastases","volume":"460","author":"Hetland","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2013.06.003_bb0165","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2013.06.003_bb0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2013.06.003_bb0175","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4161\/cbt.12.8.16440","article-title":"Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models","volume":"12","author":"Mutrie","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.humpath.2013.06.003_bb0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10555-011-9338-4","article-title":"S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence","volume":"31","author":"Mishra","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.humpath.2013.06.003_bb0185","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1517\/17460441.2012.719869","article-title":"Nanotechnology based platforms for survivin targeted drug discovery","volume":"7","author":"Samarasinghe","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.humpath.2013.06.003_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1757-2215-4-20","article-title":"Nuclear survivin expression is a positive prognostic factor in taxane-platinum\u2013treated ovarian cancer patients","volume":"4","author":"Felisiak-Golabek","year":"2011","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.humpath.2013.06.003_bb0195","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.2741\/3151","article-title":"The different functions of Stat5 and chromatin alteration through Stat5 proteins","volume":"13","author":"Kornfeld","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.humpath.2013.06.003_bb0200","first-page":"104","article-title":"The role of Stat5 transcription factors as tumor suppressors or oncogenes","volume":"2011","author":"Ferbeyre","year":"1815","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.humpath.2013.06.003_bb0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10585-010-9315-2","article-title":"Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions","volume":"27","author":"Elloul","year":"2010","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.humpath.2013.06.003_bb0210","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2013.06.003_bb0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10637-012-9837-3","article-title":"Investigational agents in development for the treatment of ovarian cancer","volume":"31","author":"Westin","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.humpath.2013.06.003_bb0220","first-page":"193","article-title":"Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3","volume":"26","author":"Sun","year":"2011","journal-title":"Oncol Rep"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817713002578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817713002578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T10:29:22Z","timestamp":1688466562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817713002578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0046817713002578"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2013.06.003","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}